Page 219 - Genentech News Today

Protein could yield potential therapeutic strategy to detect and prevent cancer therapy-associated heart failure

Encouraging findings with the combination suggest that it could offer a new standard treatment for patients with highly mutated non–small cell lung cancer.

Mosaic Brands, Inc. v. Ridge Wallet LLC, Appeal Nos. 2022-1001, -1002 (Fed. Cir. Dec. 20, 2022) - In our Case of the Week, the Federal Circuit discussed the corroboration...

Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including leukemias, lymphomas and breast cancer. Anthracyclines -- such as doxorubicin, frequently used against breast cancer -- kill cancer cells by damaging their DNA.

The Federal Circuit recently affirmed a district court judgment of invalidity for obviousness and for noninfringement for a series of patents challenged in ANDA litigation, in Genentech...

Patients with mantle cell lymphoma (MCL) who survive 2 years without disease recurrence or progression live nearly as long as age- and sex-matched individuals in the general population.

With the 2023 Washington State of Reform Health Policy Conference coming up next week, we wanted to share the list of organizations that will be attending our event.

GENENTECH, INC. V. SANDOZ INC. Before Newman, Lourie, and Prost. Appeal from the United States District Court for the District of Delaware. Summary: The...

After three years in the Castro, progressive Indian restaurant Bhoga (468 Castro St.) is calling it quits. However, the space won't sit vacant for long.

SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has approved Lunsumio (mosunetuzumab-axgb) for the treatment of adult